KYMR Kymera Therapeutics

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via , or visit “” in the Investors section of the Company’s website at . A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics 

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on or . 

Investor and Media Contact: 

Justine Koenigsberg

Vice President, Investor Relations





857-285-5300



EN
20/02/2025

Underlying

KYMRKymera Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kymera Therapeutics

 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Announces Positive First-in-Human Results from Pha...

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC...

June 2, 2025 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial...

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To...

May 30, 2025 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Participate in Upcoming June Investor Conferenc...

Kymera Therapeutics to Participate in Upcoming June Investor Conferences WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Jefferies Global Healthcare Conference in New York, NY on June 5 at 8:10 a.m. ET;Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on June 10 at 3:20 p.m. ET; andWolfe Research Virtual B...

May 29, 2025 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-...

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025 KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25 Two parallel Phase 2b trials in AD and ...

May 19, 2025 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with ...

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, ora...

May 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch